Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug-sensitive FGFR2 mutations in endometrial carcinoma.
Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H. Dutt A, et al. Among authors: wyhs n. Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7. doi: 10.1073/pnas.0803379105. Epub 2008 Jun 13. Proc Natl Acad Sci U S A. 2008. PMID: 18552176 Free PMC article.
A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs.
Giovinazzo H, Walker D, Wyhs N, Liu J, Esopi DM, Vaghasia AM, Jain Y, Bhamidipati A, Zhou J, Nelson WG, Yegnasubramanian S. Giovinazzo H, et al. Among authors: wyhs n. Oncotarget. 2019 Apr 30;10(32):3040-3050. doi: 10.18632/oncotarget.26889. eCollection 2019 Apr 30. Oncotarget. 2019. PMID: 31105884 Free PMC article.
AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.
Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, Schaeffer EM, Lotan TL, Isaacs WB, Netto GJ, De Marzo AM, Nelson WG, An SS, Yegnasubramanian S. Haffner MC, et al. Among authors: wyhs n. Nat Commun. 2017 Jul 26;8(1):142. doi: 10.1038/s41467-017-00084-8. Nat Commun. 2017. PMID: 28747635 Free PMC article.
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
Haffner MC, Bhamidipati A, Tsai HK, Esopi DM, Vaghasia AM, Low JY, Patel RA, Guner G, Pham MT, Castagna N, Hicks J, Wyhs N, Aebersold R, De Marzo AM, Nelson WG, Guo T, Yegnasubramanian S. Haffner MC, et al. Among authors: wyhs n. Prostate. 2021 Nov;81(15):1159-1171. doi: 10.1002/pros.24210. Epub 2021 Aug 16. Prostate. 2021. PMID: 34402095 Free PMC article.
An isogenic cell line panel for sequence-based screening of targeted anticancer drugs.
Cook AL, Wyhs N, Sur S, Ptak B, Popoli M, Dobbyn L, Papadopoulos T, Bettegowda C, Papadopoulos N, Vogelstein B, Zhou S, Kinzler KW. Cook AL, et al. Among authors: wyhs n. iScience. 2022 May 23;25(6):104437. doi: 10.1016/j.isci.2022.104437. eCollection 2022 Jun 17. iScience. 2022. PMID: 35692635 Free PMC article.
Personalized postdoctoral fellowship care.
Graham MK, Park BH, Wyhs N. Graham MK, et al. Among authors: wyhs n. Nat Biotechnol. 2018 Sep 6;36(9):900-902. doi: 10.1038/nbt.4228. Nat Biotechnol. 2018. PMID: 30188527 No abstract available.
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities.
Mog BJ, Marcou N, DiNapoli SR, Pearlman AH, Nichakawade TD, Hwang MS, Douglass J, Hsiue EH, Glavaris S, Wright KM, Konig MF, Paul S, Wyhs N, Ge J, Miller MS, Azurmendi P, Watson E, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Mog BJ, et al. Among authors: wyhs n. Sci Transl Med. 2024 Jul 10;16(755):eadg7123. doi: 10.1126/scitranslmed.adg7123. Epub 2024 Jul 10. Sci Transl Med. 2024. PMID: 38985855
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
Nichakawade TD, Ge J, Mog BJ, Lee BS, Pearlman AH, Hwang MS, DiNapoli SR, Wyhs N, Marcou N, Glavaris S, Konig MF, Gabelli SB, Watson E, Sterling C, Wagner-Johnston N, Rozati S, Swinnen L, Fuchs E, Pardoll DM, Gabrielson K, Papadopoulos N, Bettegowda C, Kinzler KW, Zhou S, Sur S, Vogelstein B, Paul S. Nichakawade TD, et al. Among authors: wyhs n. Nature. 2024 Apr;628(8007):416-423. doi: 10.1038/s41586-024-07233-2. Epub 2024 Mar 27. Nature. 2024. PMID: 38538786
13 results